Gregory Bailey

Gregory Bailey, M.D., is CEO of Juvenescence Limited, a company that develops therapeutics, so people can have healthier, longer lives.

Dr Bailey has been founding and financing life science companies since 1995. Some of these companies have traded on NASDAQ, AIM, AMEX and NYSE, reaching over $18 billion in market capitalization. He co-founded Ascent Health Care in 1995, which was sold to Stryker for $525 million in 2009. In 2004, he was the initial financier and a board member of Medivation, Inc. (MDVN: NASDAQ). It was ultimately acquired by Pfizer in September 2016 for $14.3 billion. In January 2014, Dr Bailey along with his partners capitalized Biohaven through Portage Biotech with $3.5 million, subsequently adding a further $3.5 million over the next two years. Biohaven went public May 2017 on NYSE. Portage was the major shareholder in Biohaven until it did a dividend of $210 million of Biohaven shares to Portage shareholders. Dr Bailey remains a major shareholder of Biohaven, which has a market cap of a little over $1.5 billion.

Along with AgeX, Gregory Bailey currently sits on the Board of Directors of three public companies: Portage Biotech, Inc. (PTGEF:OTC); SalvaRx PLC. (SALV.L:AIM); and Biohaven Pharmaceutical Holding Company Ltd. (BHVN:NYSE).

Dr Bailey received his medical doctorate from the University of Western Ontario.